erythropoetin beta

Recombinant proteinexperimental

Clinical trial activity

8 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
1

Earliest trial started Jan 1, 2004 (NCT00284271)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • erythropoetin beta

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03786289Phase 1Dec 3, 2018Fortune Rock
NCT01732146Phase 3Mar 1, 2013University of Paris
NCT00551291Phase 2Aug 1, 2007Roche
NCT00654992Phase 2/Phase 3 (Phase 3)Sep 1, 2006Seoul National University
NCT00568542Phase 4May 1, 2006Humboldt University
NCT03867071N/AOct 31, 2005Centre Hospitalier Universitaire de Nīmes
NCT00140010Phase 2Apr 1, 2005Roche, University of Cambridge
NCT00284271Phase 2Jan 1, 2004University of Cologne
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RocheFor profit2112005
Centre Hospitalier Universitaire de NīmesAcademic/Hospital1112005
Fortune RockFor profit1112018
Humboldt UniversityAcademic/Hospital1112006
Seoul National UniversityAcademic/Hospital1112006
University of CambridgeAcademic/Hospital1112005
University of CologneAcademic/Hospital1112004
University of ParisAcademic/Hospital1112013
8 organizations
Page 1 / 1